Vidora, 3 mg+0.03 mg 28 pcs

Vidora is a microdose combined monophasic hormonal contraceptive drug containing ethinyl estradiol and drospirenone. The contraceptive effect of the drug is based on the interaction of various factors, the most important of which are inhibition of ovulation, increasing the viscosity of the cervical secretion, making it impermeable to sperm.

When used correctly, the Perl Index (a measure of the number of pregnancies in 100 women using the contraceptive over the course of a year) is less than 1. If the pill is missed or used incorrectly, the Perl index may increase.

Drospirenone also has antiandrogenic and weak anti-mineralocorticoid properties at the therapeutic dose. Drospirenone has no estrogenic, glucocorticosteroid or antiglucocorticosteroid activity and has a pharmacological profile similar to that of natural progesterone.

With anti-androgenic activity the drug promotes reduction of sebum production and improvement of the clinical course in women with acne (acne vulgaris), which should be considered when choosing a contraceptive drug, especially for women with hormone-dependent fluid retention and for women with acne and seborrhea.

In combination with ethinylestradiol, it improves the lipid profile and increases the concentration of high-density lipoproteins.

Limiting menstrual bleeding, the drug helps to reduce the severity of pain and the volume of menstrual bleeding, thereby reducing one of the risk factors for iron deficiency anemia. In addition, there is evidence that the use of combined oral contraceptives (OCs) reduces the risk of endometrial cancer and ovarian cancer.

Indications

Oral contraception

Pharmacological effect

Vidora is a microdosed combined monophasic hormonal contraceptive drug containing ethinyl estradiol and drospirenone. The contraceptive effect of the drug is based on the interaction of various factors, the most important of which are inhibition of ovulation, increasing the viscosity of the cervical secretion, as a result of which it becomes impenetrable to sperm.

When used correctly, the Pearl index (an indicator reflecting the number of pregnancies in 100 women using a contraceptive drug during the year) is less than 1. If pills are missed or used incorrectly, the Pearl index may increase.

At a therapeutic dose, drospirenone also has antiandrogenic and weak antimineralocorticoid properties. Drospirenone does not have estrogenic, glucocorticosteroid or antiglucocorticosteroid activity and has a pharmacological profile similar to that of natural progesterone.

Possessing antiandrogenic activity, the drug helps reduce the production of sebaceous gland secretions and improve the clinical course in women with acne (acne vulgaris), which must be taken into account when choosing a contraceptive drug, especially for women with hormone-dependent fluid retention, as well as women with acne and seborrhea.

In combination with ethinyl estradiol, it improves the lipid profile and increases the concentration of high-density lipoproteins.

By regulating menstrual-like bleeding, the drug helps reduce the severity of pain and the volume of menstrual-like bleeding, thereby reducing one of the risk factors for the development of iron deficiency anemia. In addition, there is evidence that the use of combined oral contraceptives (COCs) reduces the risk of developing endometrial and ovarian cancer.

Active ingredient

Drospirenone, Ethinylestradiol

Composition

1 yellow film-coated tablet contains drospirenone 3.0 mg and ethinyl estradiol 0.03 mg

excipients:

lactose,

corn starch,

corn starch,

crospovidone Рlasdone XL-10 crospovidone Рlasdone XL,

povidone K-30,

polysorbate 80,

magnesium stearate,

Opadry® yellow (polyethylene glycol, polyvinyl alcohol, titanium dioxide (E 171),

talc,

iron oxide yellow (E172)).

1 film-coated tablet, white (placebo) contains

excipients:

lactose,

povidone K-30,

magnesium stearate, Opadry® II white (polyvinyl alcohol (hydrolyzed part), titanium dioxide (E 171),

macrogol 3350,

talc (E 553b)).

Overdose

At this time, there is no experience of overdose with drospirenone/ethinyl estradiol.

Based on general experience with the use of combined oral contraceptives, symptoms that can be observed with an overdose of active tablets are identified: nausea, vomiting, and in young girls, slight bleeding from the vagina.

There are no antidotes and further treatment should be symptomatic.

Manufacturer

Laboratorios Leon Pharma S.A., Spain